A global consensus has officially renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS), a change aimed at improving diagnosis and care for the condition affecting 1 in 8 women worldwide. The renaming initiative, led by experts and patient advocates, was published in The Lancet and announced at the European Congress of Endocrinology in Prague.
Immediate Action & Core Facts
The new name, PMOS, was chosen to better reflect the condition's broader impacts on hormones, metabolism, and ovarian function. The previous term, PCOS, was deemed misleading as it suggested ovarian cysts were the primary issue, despite evidence showing they are not a defining feature. The renaming process involved collaboration with 56 academic, clinical, and patient organizations, along with input from over 14,000 individuals with the condition.
Deeper Dive & Context
Why the Name Change?
Experts argue that the term PCOS oversimplified the condition, leading to misdiagnoses and inadequate treatment. PMOS emphasizes the condition's hormonal and metabolic aspects, which can lead to irregular periods, excess androgen levels, and increased risks of type 2 diabetes, heart disease, and mental health issues. Research published in The Lancet found that women with PMOS do not have a higher rate of abnormal ovarian cysts than those without the condition.
Diagnosis and Treatment Challenges
PMOS affects up to 12% of American women of reproductive age, with as many as 70% of cases remaining undiagnosed. Black and Hispanic women are more likely to experience severe metabolic complications and face delays in diagnosis. The condition's exact cause is unknown, but genetics and obesity are believed to play roles. Diagnosis involves blood work, physical exams, pelvic ultrasounds, and medical history reviews.
Global Implementation
The renaming initiative is part of a broader effort to update disease classification, education, and alignment with health systems worldwide. The Endocrine Society and the CDC estimate that 5 million to 6 million women in the U.S. have PMOS, with similar rates across racial groups. The new name aims to reduce stigma and improve care by accurately describing the condition's complex nature.